Clinical Trials Browser

Phase 1/2 × Recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × Clear all

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Phase 1/2 Recruiting

160 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03331198 2026-03-04

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Phase 1/2 Recruiting

320 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06364423 2026-03-02

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Phase 1/2 Recruiting

132 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05702853 2026-02-27

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Phase 1/2 Recruiting

27 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04186520 2026-02-23

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Phase 1/2 Recruiting

100 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06533579 2026-02-12

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Phase 1/2 Recruiting

32 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06644183 2026-02-11

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Recruiting

64 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06542250 2026-02-10

TITANium

Phase 1/2 Recruiting

174 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT06564038 2026-02-05

Soundtrack-E

Phase 1/2 Recruiting

276 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Phase 1/2 Recruiting

40 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05643742 2025-11-14

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Recruiting

120 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04329728 2025-11-03

OPAL

Phase 1/2 Recruiting

144 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoproliferative Disorders, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, T-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03765177 2025-08-14

CLIC-01

Phase 1/2 Recruiting

60 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05908409 2025-05-01

CASSANDRA

Phase 1/2 Recruiting

37 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05294731 2025-04-20

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Phase 1/2 Recruiting

146 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04494503 2025-04-16

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Phase 1/2 Recruiting

123 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06506643 2024-10-01

Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms

Phase 1/2 Recruiting

36 enrolled

DermatologicGastrointestinalGenitourinaryLymphoidOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03676504 2024-07-29

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Phase 1/2 Recruiting

68 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05959694 2023-10-23

A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

Phase 1/2 Recruiting

107 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04771507 2021-02-25

IbruOnOff

Phase 1/2 Recruiting

50 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

CaDAnCe-101

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

TITANium

Soundtrack-E

Mosunetuzumab for CLL MRD Clearance

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

OPAL

CLIC-01

CASSANDRA

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

IbruOnOff